Selected research
Industry Growth & Trends
Global Lacosamide Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Lacosamide market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Lacosamide is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Lacosamide is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Lacosamide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Lacosamide market include UCB, Teva, Sun Pharma, Mylan, MSN Laboratories, Glenmark, Aurobindo Pharma, Apotex and Amneal Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Lacosamide market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Lacosamide market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Lacosamide market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Lacosamide.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Lacosamide market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Lacosamide Market by Company
UCB
Teva
Sun Pharma
Mylan
MSN Laboratories
Glenmark
Aurobindo Pharma
Apotex
Amneal Pharmaceuticals
Alembic Pharma
Accord Healthcare
Lacosamide Segment by Type
Intravenous
Oral tablets
Oral solution
Lacosamide Segment by Application
Adults
Pediatric patients
Lacosamide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lacosamide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lacosamide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lacosamide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Lacosamide companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Intravenous
- Oral tablets
- Oral solution
Applications
- Adults
- Pediatric patients
Companies covered
- UCB
- Teva
- Sun Pharma
- Mylan
- MSN Laboratories
- Glenmark
- Aurobindo Pharma
- Apotex
- Amneal Pharmaceuticals
- Alembic Pharma
- Accord Healthcare
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Lacosamide Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Lacosamide Market Size by Region (2021-2032)
- 1.4.1 Global Lacosamide Market Size by Region (2021-2026)
- 1.4.2 Global Lacosamide Market Size by Region (2027-2032)
- 1.5 Key Regions Lacosamide Market Size (2021-2032)
- 1.5.1 North America Lacosamide Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Lacosamide Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Lacosamide Market Size Growth Rate (2021-2032)
- 1.5.4 South America Lacosamide Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Lacosamide Market Size Growth Rate (2021-2032)
2 Lacosamide Market by Type
- 2.1 Type Introduction
- 2.1.1 Intravenous
- 2.1.2 Oral tablets
- 2.1.3 Oral solution
- 2.2 Global Lacosamide Market Size by Type
- 2.2.1 Global Lacosamide Market Size Overview by Type (2021-2032)
- 2.2.2 Global Lacosamide Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Lacosamide Market Size Forecasted by Type (2027-2032)
- 2.3 Global Lacosamide Market Size by Regions
- 2.3.1 North America Lacosamide Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Lacosamide Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Lacosamide Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Lacosamide Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Lacosamide Market Size Breakdown by Type (2021-2026)
3 Lacosamide Market by Application
- 3.1 Type Introduction
- 3.1.1 Adults
- 3.1.2 Pediatric patients
- 3.2 Global Lacosamide Market Size by Application
- 3.2.1 Global Lacosamide Market Size Overview by Application (2021-2032)
- 3.2.2 Global Lacosamide Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Lacosamide Market Size Forecasted by Application (2027-2032)
- 3.3 Global Lacosamide Market Size by Regions
- 3.3.1 North America Lacosamide Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Lacosamide Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Lacosamide Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Lacosamide Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Lacosamide Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Lacosamide Industry Trends
- 4.2 Lacosamide Industry Drivers
- 4.3 Lacosamide Industry Opportunities and Challenges
- 4.4 Lacosamide Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Lacosamide Revenue (2021-2026)
- 5.2 Global Lacosamide Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Lacosamide Key Company Headquarters & Area Served
- 5.4 Global Lacosamide Company, Product Type & Application
- 5.5 Global Lacosamide Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Lacosamide Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Lacosamide Players Market Share by Revenue in 2025
- 5.6.3 2025 Lacosamide Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 UCB
- 6.1.1 UCB Company Information
- 6.1.2 UCB Business Overview
- 6.1.3 UCB Lacosamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 UCB Lacosamide Product Portfolio
- 6.1.5 UCB Recent Developments
- 6.2 Teva
- 6.2.1 Teva Company Information
- 6.2.2 Teva Business Overview
- 6.2.3 Teva Lacosamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Teva Lacosamide Product Portfolio
- 6.2.5 Teva Recent Developments
- 6.3 Sun Pharma
- 6.3.1 Sun Pharma Company Information
- 6.3.2 Sun Pharma Business Overview
- 6.3.3 Sun Pharma Lacosamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Sun Pharma Lacosamide Product Portfolio
- 6.3.5 Sun Pharma Recent Developments
- 6.4 Mylan
- 6.4.1 Mylan Company Information
- 6.4.2 Mylan Business Overview
- 6.4.3 Mylan Lacosamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Mylan Lacosamide Product Portfolio
- 6.4.5 Mylan Recent Developments
- 6.5 MSN Laboratories
- 6.5.1 MSN Laboratories Company Information
- 6.5.2 MSN Laboratories Business Overview
- 6.5.3 MSN Laboratories Lacosamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 MSN Laboratories Lacosamide Product Portfolio
- 6.5.5 MSN Laboratories Recent Developments
- 6.6 Glenmark
- 6.6.1 Glenmark Company Information
- 6.6.2 Glenmark Business Overview
- 6.6.3 Glenmark Lacosamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Glenmark Lacosamide Product Portfolio
- 6.6.5 Glenmark Recent Developments
- 6.7 Aurobindo Pharma
- 6.7.1 Aurobindo Pharma Company Information
- 6.7.2 Aurobindo Pharma Business Overview
- 6.7.3 Aurobindo Pharma Lacosamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Aurobindo Pharma Lacosamide Product Portfolio
- 6.7.5 Aurobindo Pharma Recent Developments
- 6.8 Apotex
- 6.8.1 Apotex Company Information
- 6.8.2 Apotex Business Overview
- 6.8.3 Apotex Lacosamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Apotex Lacosamide Product Portfolio
- 6.8.5 Apotex Recent Developments
- 6.9 Amneal Pharmaceuticals
- 6.9.1 Amneal Pharmaceuticals Company Information
- 6.9.2 Amneal Pharmaceuticals Business Overview
- 6.9.3 Amneal Pharmaceuticals Lacosamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Amneal Pharmaceuticals Lacosamide Product Portfolio
- 6.9.5 Amneal Pharmaceuticals Recent Developments
- 6.10 Alembic Pharma
- 6.10.1 Alembic Pharma Company Information
- 6.10.2 Alembic Pharma Business Overview
- 6.10.3 Alembic Pharma Lacosamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Alembic Pharma Lacosamide Product Portfolio
- 6.10.5 Alembic Pharma Recent Developments
- 6.11 Accord Healthcare
- 6.11.1 Accord Healthcare Company Information
- 6.11.2 Accord Healthcare Business Overview
- 6.11.3 Accord Healthcare Lacosamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Accord Healthcare Lacosamide Product Portfolio
- 6.11.5 Accord Healthcare Recent Developments
7 North America
- 7.1 North America Lacosamide Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Lacosamide Market Size by Country (2021-2026)
- 7.3 North America Lacosamide Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Lacosamide Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Lacosamide Market Size by Country (2021-2026)
- 8.3 Europe Lacosamide Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Lacosamide Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Lacosamide Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Lacosamide Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Lacosamide Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Lacosamide Market Size by Country (2021-2026)
- 10.3 South America Lacosamide Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Lacosamide Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Lacosamide Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Lacosamide Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst